Clinical Progress Accelerates for Vigil Neuroscience's Alzheimer's Candidate Vigil Neuroscience has advanced its oral small molecule TREM2 agonist, VG-3927, into Phase 2 trials after promising Phase 1 results showed strong safety and biomarker improvements. The company, which ended 2024 with nearly $98 million in cash, aims to launch the next trial phase in Q3 2025.12